| 基于生物信息学分析SLC7A5在乳腺癌中的表达和预后价值 |
| 投稿时间：2025-03-19 修订日期：2025-04-11 点此下载全文 |
| 引用本文：王柳,马志军.基于生物信息学分析SLC7A5在乳腺癌中的表达和预后价值[J].医学研究杂志,2025,54(9):36-43, 197 |
| DOI：
10.11969/j.issn.1673-548X.2025.09.008 |
| 摘要点击次数: 45 |
| 全文下载次数: 25 |
|
| 基金项目:国家自然科学基金地区基金资助项目(82060485) |
|
| 中文摘要:目的 通过生物信息学分析SLC7A5在乳腺癌中的表达及其与临床病理特征的相关性,为乳腺癌的治疗及预后评估提供参考。方法 在Timer2.0、癌症基因组图谱(the cancer genome atlas, TCGA)、UALAN在基因表达谱交互式分析(gene expression profiling interactive analysis 2,GEPIA2)和人类蛋白质表达图谱(human protein atlas, HPA)等数据库中获取SLC7A5在乳腺癌中的表达特征。使用Western blot法检测SLC7A5基因在正常乳腺细胞MCF-10A和乳腺癌细胞株 MCF-7中的表达情况。使用R软件分析SLC7A5在乳腺癌中的预后价值,在Kaplan-Meier Plotter 和基因表达数据库(gene expression omnibus,GEO)中进行双重验证,同时分析其表达与乳腺癌患者不同病理特征之间的相关性。运用R语言分析SLC7A5与肿瘤突变负荷(tumor mutation burden,TMB)及免疫检测点相关基因的相关性,并进行基因集富集分析(gene set enrichment analysis,GSEA),并对分析结果进一步可视化处理。结果 SLC7A5在包括乳腺癌在内的多种实体恶性肿瘤中表达升高,高表达SLC7A5的乳腺癌患者总生存期缩短。SLC7A5在乳腺癌中的表达水平与乳腺癌雌激素受体、孕激素受体、淋巴结转移及分子分型相关。TMB结果提示,SLC7A5在乳腺癌中的表达与TMB呈正相关(r=0.33,P<0.001)。免疫检查点分析结果表明,SLC7A5的表达量与程序性死亡受体 1(programmed death-1,PD-1)、细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte-associated antigen 4,CTLA4)、B和T细胞衰减因子(B and T lymphocyte attenuator,BTLA)等呈正相关。GSEA富集分析结果显示SLC7A5主要与干扰素γ反应相关通路相关。结论 SLC7A5在乳腺癌中表达上调,其表达水平与不良预后相关,可能通过参与干扰素γ反应相关通路促进免疫检查点的表达影响乳腺癌的进展,其或可作为为乳腺癌患者预后评估和指导治疗的生物学标志物。 |
| 中文关键词:乳腺癌 SLC7A5 生物信息学 预后 免疫检查点 |
| |
| Bioinformatics-based Analysis of SLC7A5 Expression and Prognostic Value in Breast Cancer |
|
|
| Abstract:Objective To analyze the correlation between SLC7A5 expression and clinicopathological features in breast cancer by bioinformatics, and to provide reference for the treatment and prognosis evaluation of breast cancer. Methods The expression of SLC7A5 in breast cancer was analyzed by bioinformatics in Timer2.0, The cancer genome atlas (TCGA), UALAN in gene expression profiling interactive analysis 2 (GEPIA2) and human protein atlas (HPA). Human protein atlas (HPA) and other databases to obtain the expression characteristics of SLC7A5 in breast cancer. Western blot was used to detect the expression of SLC7A5gene in normal breast cells MCF-10A and breast cancer cell line MCF-7. the prognostic value of SLC7A5 in breast cancer was analyzed by using R software, and double-validated in Kaplan-Meier plotter and gene expression omnibus (GEO) databases. validation, as well as analyzing the correlation between its expression and different pathological features of breast cancer patients. The correlation between SLC7A5 and tumor mutation burden (TMB) and immunodetection point-related genes was analyzed using R language, and gene set enrichment analysis (GSEA) was performed, and the results were further visualized. Results The expression of SLC7A5 was significantly elevated in a variety of solid malignant tumors, including breast cancer, and the overall survival of breast cancer patients with high expression of SLC7A5 was significantly shortened. The expression level of SLC7A5 in breast cancer was significantly correlated with estrogen receptor (ER), progesterone receptor (PR), lymph node metastasis, and molecular typing of breast cancer. The results showed that the expression of SLC7A5 in breast cancer was positively correlated with TMB (r=0.33, P<0.001). The results of the immune checkpoint analysis showed that the expression of SLC7A5 was significantly correlated with the expression of programmed death-1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (cytotoxic T lymphocyte-associated protein 4 (cytotoxic T lymphocyte-associated protein 4), and the expression of SLC7A5 was significantly correlated with the expression of ER, PR, lymph node metastasis and molecular typing. cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and B and T lymphocyte attenuator (BTLA). GSEA enrichment analysis showed that SLC7A5 was mainly associated with the interferon γ response (IFN-γ) related pathway.Conclusion SLC7A5 is up-regulated in breast cancer, and its expression level correlates with poor prognosis, which may affect the progression of breast cancer by participating in the IFN-γ-related pathway to promote the expression of immune checkpoints, and it may be used as a biomarker for prognostic assessment and guidance of treatment for breast cancer patients. |
| keywords:Breast cancer Slc7a5 Bioinformatics Prognosis Immune checkpoint |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
